Crescent Biopharma (CBIO) Revenue & Revenue Breakdown
Crescent Biopharma Revenue Highlights
00
Main Segment (Y)
Reportable Segment
Crescent Biopharma Revenue by Period
Crescent Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | - | 100.00% |
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $10.00K | -86.67% |
| 2022-12-31 | $75.00K | -93.53% |
| 2021-12-31 | $1.16M | -88.59% |
| 2020-12-31 | $10.16M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $18.50K | -99.91% |
| 2015-12-31 | $20.07M | 33.56% |
| 2014-12-31 | $15.03M | 276.37% |
| 2013-12-31 | $3.99M | -73.83% |
| 2012-12-31 | $15.26M | 300.04% |
| 2011-12-31 | $3.81M | - |
Crescent Biopharma generated - in revenue during NA 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Crescent Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | - | -100.00% |
| 2026-03-31 | $1.04M | -90.42% |
| 2025-12-31 | $10.84M | 100.00% |
| 2025-09-30 | - | 100.00% |
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $10.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $75.00K | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $17.63K | -79.64% |
| 2021-09-30 | $86.56K | 60857.75% |
| 2021-06-30 | $142.00 | -99.99% |
| 2021-03-31 | $1.06M | 547.77% |
| 2020-12-31 | $162.94K | -83.71% |
| 2020-09-30 | $1.00M | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $9.00M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Crescent Biopharma generated - in revenue during Q2 2026, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Crescent Biopharma Revenue Breakdown
Crescent Biopharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Reportable Segment | $10.84M | - |
| Product | - | $105.80M |
Latest
Crescent Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 |
|---|---|---|---|---|---|
| Pharmaceutical Products | $29.10M | - | - | - | - |
| Reportable Segment | - | $1.04M | $8.05M | $2.79M | - |
| Product | - | - | - | $30.60M | $26.80M |
Latest
Crescent Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Pharmaceutical Products (100.00%).
Crescent Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRTX | Heron Therapeutics | $154.90M | $37.67M |
| SGMO | Sangamo Therapeutics | $57.80M | $1.44M |
| IPHA | Innate Pharma | $51.90M | $16.56M |
| CGEN | Compugen | $33.46M | $2.56M |
| OABI | OmniAb | $18.67M | $13.41M |
| TNXP | Tonix Pharmaceuticals | $13.11M | $13.54M |
| IMDX | Insight Molecular Diagnostics | $4.05M | $239.00K |
| HIND | Vyome | $319.71K | $26.95K |
| CCCC | C4 Therapeutics | - | $6.64M |
| CBIO | Crescent Biopharma | - | - |